437 related articles for article (PubMed ID: 25962155)
21. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Teoh D; Ayeni TA; Rubatt JM; Adams DJ; Grace L; Starr MD; Barry WT; Berchuck A; Murphy SK; Secord AA
Gynecol Oncol; 2011 Apr; 121(1):187-92. PubMed ID: 21208651
[TBL] [Abstract][Full Text] [Related]
22. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Ebata T; Yonemori K; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Fujiwara Y; Kato T; Hasegawa K; Fujiwara K; Tamura K
Oncology; 2020; 98(10):699-705. PubMed ID: 32526764
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy in the treatment of ovarian carcinosarcoma].
Melilli GA; Di Vagno G; Cormio G; Greco P; Fontana A; Carriero C; Loverro G; Selvaggi L
Minerva Ginecol; 1999 Nov; 51(11):445-8. PubMed ID: 10726444
[TBL] [Abstract][Full Text] [Related]
24. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
25. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
[TBL] [Abstract][Full Text] [Related]
26. A rare case of ovarian carcinosarcoma with squamous cell carcinoma.
Daimon A; Fujiwara S; Tanaka Y; Tanaka T; Ohmichi M
J Ovarian Res; 2019 Apr; 12(1):32. PubMed ID: 30947745
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
28. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
Carrara L; Guzzo F; Roque DM; Bellone S; Emiliano C; Sartori E; Pecorelli S; Schwartz PE; Rutherford TJ; Santin AD
Gynecol Oncol; 2012 Apr; 125(1):231-6. PubMed ID: 22209775
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Lorusso D; Martinelli F; Mancini M; Sarno I; Ditto A; Raspagliesi F
Int J Gynecol Cancer; 2014 Sep; 24(7):1256-61. PubMed ID: 25078338
[TBL] [Abstract][Full Text] [Related]
30. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.
Dobbin ZC; Katre AA; Steg AD; Erickson BK; Shah MM; Alvarez RD; Conner MG; Schneider D; Chen D; Landen CN
Oncotarget; 2014 Sep; 5(18):8750-64. PubMed ID: 25209969
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
Lacour RA; Euscher E; Atkinson EN; Sun CC; Ramirez PT; Coleman RL; Brown J; Gano JB; Burke TW; Ramondetta LM
Int J Gynecol Cancer; 2011 Apr; 21(3):517-22. PubMed ID: 21436700
[TBL] [Abstract][Full Text] [Related]
32. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
33. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
[TBL] [Abstract][Full Text] [Related]
34. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
35. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
36. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
37. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
38. A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide.
Okazawa M; Masuhara K; Miyoshi A; Fujiwara K; Ohta Y; Yoshino K; Kamiura S; Tomita Y
J Obstet Gynaecol; 2011; 31(3):274-5. PubMed ID: 21417665
[No Abstract] [Full Text] [Related]
39. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Jain HV; Meyer-Hermann M
Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
[TBL] [Abstract][Full Text] [Related]
40. Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.
Kulkarni-Datar K; Orsulic S; Foster R; Rueda BR
Cancer Lett; 2013 Oct; 339(2):237-46. PubMed ID: 23791886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]